CrystalsFirst is redefining small molecule drug discovery with its MAGNET Platform, a breakthrough technology platform. By integrating proprietary structural biology, and generative AI, we identify novel druggable binding pockets and precisely design molecules for even the most challenging targets. At the core of our platform is a “crystal structure first” strategy, enabling structure-based drug discovery from the outset. By leveraging high-resolution structural insights, large-scale computational modeling, and AI-driven molecular design, we accelerate the identification and optimization of lead compounds with superior therapeutic potential. By combining these synergistic technologies, the MAGNET Platform enhances efficiency, reduces risk, and significantly increases the probability of identifying first-in-class and best-in-class therapeutics. We are setting a new standard in drug discovery—bridging structural insights with AI-driven innovation to deliver transformative medicines.